[CGIX] Cancer Genetics, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Medical Specialities

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 1.4 Change: 0 (0%)
Ext. hours: Change: 0 (0%)

chart CGIX

Refresh chart

Strongest Trends Summary For CGIX

CGIX is in the medium-term down -28% below S&P in 5 months and down -79% below S&P in 1 year. In the long-term down -96% below S&P in 3 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Cancer Genetics, Inc., an early-stage diagnostics company, focuses on developing and commercializing proprietary genomic tests and services to improve and personalize the diagnosis, prognosis, and response to treatment of cancer. The company offers a range of services in various areas, including microarray based testing, a proprietary microarray tests for the detection of chromosomal abnormalities observed in chronic lymphocytic leukemia, small lymphocytic lymphoma diffuse large B-cell lymphoma, mantle cell lymphoma, and kidney cancer. It also provides molecular testing services, such as polymerase chain reaction, sequencing, and mutahine analysis to analyze DNA and RNA, as well as to follow progression of disease and response to therapy at the genetic level; and cytogenetics testing, a series of methods that analyze human chromosomes in order to identify malignancy. In addition, the company provides FISH testing, an analysis of abnormalities at the chromosomal and gene levels; and flow cytometry testing, an

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 189.02% Sales Growth - Q/Q8.3% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-42.68% ROE-59.52% ROI-48.57%
Current Ratio6.93 Quick Ratio Long Term Debt/Equity0.29 Debt Ratio0.13
Gross Margin21.56% Operating Margin-147.84% Net Profit Margin-140.31% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-10 K Cash From Investing Activities-120 K Cash From Operating Activities-3.1 M Gross Profit1.23 M
Net Profit-4.28 M Operating Profit-4.15 M Total Assets43.19 M Total Current Assets28.29 M
Total Current Liabilities4.08 M Total Debt6.98 M Total Liabilities12.22 M Total Revenue4.37 M
Technical Data
High 52 week1.26 Low 52 week0.2 Last close0.21 Last change0.19%
RSI42.26 Average true range0.03 Beta1.16 Volume138.35 K
Simple moving average 20 days-6.82% Simple moving average 50 days-13.92% Simple moving average 200 days-59.38%
Performance Data
Performance Week-4.76% Performance Month-13.47% Performance Quart-18.92% Performance Half-65%
Performance Year-77.05% Performance Year-to-date-13.22% Volatility daily4.94% Volatility weekly11.05%
Volatility monthly22.64% Volatility yearly78.44% Relative Volume209.6% Average Volume1.52 M
New High New Low

News

2019-06-05 02:00:06 | LabCorp LH Closes Envigo Swap Deal, Expands in CRO Space

2019-05-20 17:06:16 | Cancer Genetics: 1Q Earnings Snapshot

2019-05-20 17:00:00 | Cancer Genetics Reports First Quarter 2019 Financial Results and Provides Strategic Business Update

2019-04-16 07:22:15 | Cancer Genetics: 4Q Earnings Snapshot

2019-04-16 07:00:00 | Cancer Genetics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Strategic Business Updates

2019-03-26 08:06:54 | Investors Who Bought Cancer Genetics NASDAQ:CGIX Shares Five Years Ago Are Now Down 98%

2019-02-14 07:04:48 | Could The Cancer Genetics, Inc. NASDAQ:CGIX Ownership Structure Tell Us Something Useful?

2019-01-31 16:01:00 | Cancer Genetics, Inc. Announces Closing of Public Offering of Common Stock

2019-01-29 07:25:36 | The Daily Biotech Pulse: Big Pharma Earnings, Kiniksa Offering, FDA Decision Day For Aquestive

2019-01-28 22:33:52 | Cancer Genetics, Inc. Announces Pricing of $3.5 Million Public Offering of Common Stock

2019-01-28 16:00:00 | Cancer Genetics, Inc. Announces Proposed Public Offering of Common Stock

2019-01-21 09:21:36 | Insider Buys Of The Week: Cancer Genetics, Dish Network, Valvoline

2019-01-16 08:45:00 | Cancer Genetics Issues Letter to Shareholders

2019-01-14 17:29:31 | Cancer Genetics, Inc. Announces Closing of Public Offering of Common Stock

2019-01-10 08:27:52 | The Daily Biotech Pulse: Cancer Genetics Prices Offering, DiaMedica Delists From Canadian Exchange, Medigus CEO Quits

2019-01-09 23:20:25 | Cancer Genetics, Inc. Announces Pricing of Public Offering of Common Stock

2019-01-09 16:00:00 | Cancer Genetics, Inc. Announces Proposed Public Offering of Common Stock

2019-01-09 08:00:00 | Cancer Genetics Strengthens Management Team with Appointment of William Finger as Executive Vice President, Precision Medicine and Pharma Services

2018-12-17 08:00:00 | Cancer Genetics Terminates Proposed Merger with NovellusDx

2018-12-14 06:55:00 | Today's Research Reports on Trending Tickers: Adial Pharmaceuticals and Cancer Genetics

2018-11-21 08:04:35 | The Daily Biotech Pulse: Mylan Recalls Blood Pressure Drug, Heat Biologics Offering, New Novelion CEO

2018-11-19 17:40:10 | Cancer Genetics CGIX Reports Q3 Loss, Lags Revenue Estimates

2018-11-19 16:33:40 | Cancer Genetics: 3Q Earnings Snapshot

2018-11-19 16:16:40 | Cancer Genetics Reports Third Quarter 2018 Financial Results and Provides Strategic Business Updates

2018-11-14 16:01:00 | Cancer Genetics Appoints Glenn Miles as Chief Financial Officer

2018-11-01 11:28:03 | Will Cancer Genetics CGIX Report Negative Earnings Next Week? What You Should Know

2018-10-18 09:05:00 | Cancer Genetics Enters Strategic Partnership with Genecast Biotechnology to Commercialize Tissue of Origin® Test in China

2018-10-16 08:00:00 | Cancer Genetics Issues Letter to Shareholders

2018-10-08 07:00:00 | Cancer Genetics and Cellaria Partner on Precision Medicine Tools

2018-09-28 18:31:00 | Robbins Arroyo LLP: Cancer Genetics, Inc. CGIX Sued by Shareholders in Recently Filed Class Action

2018-09-25 16:01:00 | Cancer Genetics Enters Supply Agreement with Agilent Technologies

2018-09-20 08:30:00 | Cancer Genetics Offers Oncomine Comprehensive Assay to Drive Clinical Trials

2018-09-18 12:14:00 | Chardan Advises NovellusDX in Cross-Border Biotech Merger

2018-09-18 08:30:00 | Cancer Genetics and NovellusDx Sign Definitive Agreement to Merge

2018-08-17 11:51:59 | Four years after buying Morrisville firm, this out-of-town CEO wants to bolster NC ops

2018-08-14 11:30:17 | Edited Transcript of CGIX earnings conference call or presentation 14-Aug-18 12:30pm GMT

2018-08-14 07:49:35 | Cancer Genetics: 2Q Earnings Snapshot

2018-08-14 07:30:00 | Cancer Genetics Reports Second Quarter 2018 Financial Results and Provides Strategic Business Updates

2018-08-14 06:30:00 | Cancer Genetics, Inc. to Host Earnings Call

2018-08-13 14:33:01 | Cancer Genetics Q2 Earnings Preview

2018-08-07 16:05:00 | Cancer Genetics to Report Second Quarter 2018 Financial Results on August 14, 2018

2018-07-18 16:05:00 | Cancer Genetics Closes $2.625 million Convertible Note Financing

2018-07-12 07:25:00 | Free Research Reports on DexCom and Three More Medical Research Stocks

2018-06-12 08:00:00 | Cancer Genetics Strengthens Management Team with Appointment of Michael McCartney as Chief Commercial Officer

2018-06-04 16:00:00 | Deadline Alert: Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against Cancer Genetics, Inc. CGIX

2018-06-04 13:30:00 | DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Cancer Genetics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

2018-06-04 10:27:00 | FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Cancer Genetics, Inc. CGIX and Lead Plaintiff Deadline - June 4, 2018

2018-06-01 20:00:00 | 3-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Cancer Genetics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

2018-06-01 19:15:00 | SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cancer Genetics, Inc. of Class Action Lawsuit and Upcoming Deadline – CGIX

2018-06-01 16:06:00 | CANCER GENETICS LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 in Cancer Genetics, Inc. to Contact the Firm